Dapagliflozin reduces cardiovascular death risk in patients with preserved ejection fraction
Results were presented at European Society of Cardiology Congress 2022, and published in 'New England Journal of Medicine'
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
dapagliflozin
Dapagliflozin meets primary endpoint in Deliver phase-III trial
Reduces risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction
Japan approves Forxiga to treat chronic kidney disease in patients with and without type-II diabetes
Forxiga is the first-ever approved medicine for the treatment of the disease in Japan
Astrazeneca gives rights to trademark for three diabetes drug brands to Sun Pharma
Consequently, AstraZeneca India and Sun Pharma have discontinued their existing distribution services agreement signed in 2016,…
AstraZeneca gets US FDA nod for FARXIGA to treat chronic kidney disease
In DAPA-CKD Phase III trial, FARXIGA demonstrated reduction in the risk of the composite of worsening of renal function, end-stage…
Micro Labs launches anti-diabetic drug combo, Dapagliflozin plus Metformin
The drug comes in two strengths ZUCAPRIDE–M 500 priced at Rs12.80 per tablet and ZUCAPRIDE–M 1000 at Rs 14.80
SGLT-2 inhibitors may primarily drive growth of branded heart failure treatment market: GlobalData
Approximately 55 per cent of type T2D patients suffer from cardiovascular disease (CVD), which often leads to further…
Diabetes drug, Dapagliflozin shows benefits in patients with CKD
The drug, on top of standard of care, reduced the composite measure of worsening of renal function or risk of cardiovascular (CV)…
Glenmark gets tentative USFDA approval for generic anti-diabetes tablets
The approval is for the strength of 10 mg/5 mg tablets
Glenmark, Torrent Pharma ink licensing pact to co-market diabetes drug in India
Glenmark will manufacture and supply Remogliflozin while Torrent will market the drug under its own trademark 'Zucator' in India…